Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HealthLynked CorpHLYK · Entity 8075 | Director | November 22, 2021 | November 24, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HealthLynked Corp
Report date November 22, 2021 · Filed November 24, 2021 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 638,604 |
Reported balance
After 2021-11-22 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2021-11-22 · Grant · Acquired 74,766 · Balance 638,604 F1: This amendment is being filed to correct the number of shares included in the grant and the date of grant previously reported on the original Form 4 that was filed with the U.S. Securities and Exchange Commission on November 16, 2021. F2: Shares vest 25% on 12/31/2021, 25% on 3/31/2022, 25% on 6/30/2022 and 25% on 9/30/2022. |
Filing footnotes · ownership attribution and instrument terms
F1: This amendment is being filed to correct the number of shares included in the grant and the date of grant previously reported on the original Form 4 that was filed with the U.S. Securities and Exchange Commission on November 16, 2021.
F2: Shares vest 25% on 12/31/2021, 25% on 3/31/2022, 25% on 6/30/2022 and 25% on 9/30/2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 22, 2021 Filed Nov 24, 2021 21:11 UTC Amendment | HealthLynked Corp HLYK · Entity 8075 | GrantCommon Stock | 74,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-061950 · ownership.xml · nonDerivative · entry 1 Mino Robert P. · CIK 0001804202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,604 F1 · date: This amendment is being filed to correct the number of shares included in the grant and the date of grant previously reported on the original Form 4 that was filed with the U.S. Securities and Exchange Commission on November 16, 2021. F2 · shares: Shares vest 25% on 12/31/2021, 25% on 3/31/2022, 25% on 6/30/2022 and 25% on 9/30/2022. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:14 UTC | HealthLynked Corp HLYK · Entity 8075 | GrantCommon Stock | 68,942 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-060016 · ownership.xml · nonDerivative · entry 1 Mino Robert P. · CIK 0001804202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,780 Read SEC document |
| April 30, 2021 Filed May 4, 2021 19:47 UTC | HealthLynked Corp HLYK · Entity 8075 | GrantCommon Stock | 289,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-024484 · ownership.xml · nonDerivative · entry 1 Mino Robert P. · CIK 0001804202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 482,551 Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 22:19 UTC | HealthLynked Corp HLYK · Entity 8075 | PurchaseWarrant (right to buy) · Derivative | 25,000 | $0.50 Strike: $0.60 | $12,500.00 |
DisclosureSEC source: 0001213900-21-013218 · ownership.xml · derivative · entry 2 Mino Robert P. · CIK 0001804202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,429 Underlying: Common Stock · 25,000 shares Expires 2026-03-01 F1 · price: Shares were purchased as 50,000 shares for $0.50 per share. Each unit consists of two shares of common stock and one warrant to purchase one warrant share of common stock at $0.60 per warrant share. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 22:19 UTC | HealthLynked Corp HLYK · Entity 8075 | PurchaseCommon Stock | 50,000 | $0.50 | $25,000.00 |
DisclosureSEC source: 0001213900-21-013218 · ownership.xml · nonDerivative · entry 1 Mino Robert P. · CIK 0001804202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,857 F1 · price: Shares were purchased as 50,000 shares for $0.50 per share. Each unit consists of two shares of common stock and one warrant to purchase one warrant share of common stock at $0.60 per warrant share. Read SEC document |
| January 03, 2020 Filed Mar 3, 2020 21:13 UTC | HealthLynked Corp HLYK · Entity 8075 | GrantWarrant (right to buy) · Derivative | 71,429 | $0.09 Strike: $0.24 | $6,214.32 |
DisclosureSEC source: 0001213900-20-005282 · ownership.xml · derivative · entry 2 Mino Robert P. · CIK 0001804202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,429 Underlying: Common Stock · 1,200,000 shares Expires 2025-01-02 Read SEC document |
| January 03, 2020 Filed Mar 3, 2020 21:13 UTC | HealthLynked Corp HLYK · Entity 8075 | GrantCommon Stock | 142,857 | $0.14 | $19,999.98 |
DisclosureSEC source: 0001213900-20-005282 · ownership.xml · nonDerivative · entry 1 Mino Robert P. · CIK 0001804202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,857 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.